8-K: Organon & Co. Q3 2026 Supplemental Financials Released

Organon & Co. has released supplemental non-GAAP financial information for the quarter ended September 30, 2026, providing additional insights into its operational performance alongside its Form 10-Q filing.

Summary

• Organon & Co. is providing supplemental non-GAAP financial metrics for the quarter ended September 30, 2026, in lieu of a traditional earnings press release due to its pending merger with Sun Pharmaceutical Industries Limited.
• These non-GAAP measures, including Adjusted EBITDA, Adjusted Gross Margin, and Adjusted Diluted EPS, are presented to enhance understanding of the company's underlying business performance.
• The company emphasizes that these non-GAAP measures should be considered alongside, and not as a substitute for, its GAAP financial results.
• Key non-GAAP metrics for the three months ended September 30, 2026, include Adjusted Gross Profit of $938 million and Adjusted EBITDA of $502 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily due to the provision of supplemental non-GAAP metrics that offer a clearer view of operational performance, despite a slight dip in some adjusted metrics compared to the prior year.

Positives

• The company is providing supplemental non-GAAP financial information, which can offer a more granular view of operational performance.
• Adjusted Gross Margin for the three months ended September 30, 2026, was 59.6%, indicating a strong underlying profitability before certain adjustments.
• Adjusted EBITDA for the three months ended September 30, 2026, was $502 million, demonstrating a solid operational cash flow generation capability.

Negatives

• Adjusted Gross Profit decreased to $938 million for the three months ended September 30, 2026, from $966 million in the prior year period.
• Adjusted EBITDA decreased to $502 million for the three months ended September 30, 2026, from $518 million in the prior year period.
• Adjusted Diluted EPS for the three months ended September 30, 2026, was $0.94, down from $1.01 in the same period last year.

Risks

• The pending merger with Sun Pharmaceutical Industries Limited introduces integration risks and potential disruptions to normal business operations.
• Costs related to the pending merger with Sun Pharmaceutical Industries Limited are noted as 'Other costs' impacting Adjusted EBITDA.
• Manufacturing network related costs, including those from exiting agreements with Merck & Co., Inc., continue to be a factor in financial adjustments.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond referencing that the Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements regarding the Company and includes a cautionary statement identifying important factors that could cause actual results to differ materially from those anticipated.

Management Comments

• The Company believes that these supplemental measures assist in understanding its financial performance, but that such measures should not be considered as a substitute for the Company's financial results prepared in accordance with U.S. generally accepted accounting principles (GAAP).
• The Company makes use of the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Gross Margin, Adjusted Gross Profit, Adjusted net income, Adjusted diluted EPS, Adjusted Selling, general and administrative expenses, and Adjusted Research and development expenses, which are not recognized terms under GAAP and are presented only as a supplement to the Company's GAAP financial statements.
• The Company believes that these non-GAAP financial measures, which exclude certain items, help to enhance its ability to meaningfully communicate its underlying business performance, financial condition and results of operations.
• The Company's management uses the non-GAAP financial measures described above to evaluate the Company's performance and to guide operational and financial decision making.

Industry Context

StockSavvy.ai notes that the practice of providing supplemental non-GAAP metrics is common in the pharmaceutical and healthcare sectors to bridge the gap between reported GAAP figures and operational performance, especially during periods of significant corporate activity like mergers.

Related Party Transactions

• Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US.

Stakeholder Impact

• Shareholders: The supplemental financial information may provide greater clarity on operational performance, but the slight decrease in adjusted metrics and EPS could be a concern.
• Creditors: The Adjusted EBITDA figures provide insight into the company's ability to service debt, with a slight decrease noted.
• Employees: The ongoing merger process and associated restructuring charges could impact employee morale and job security.

Next Steps

• The company has filed its Quarterly Report on Form 10-Q with the SEC.
• The pending merger with Sun Pharmaceutical Industries Limited is an ongoing event that will likely lead to future disclosures and integration activities.

Key Dates

Recommendation

The filing provides supplemental financial data but does not offer new strategic direction or significant positive catalysts. The slight year-over-year decrease in key adjusted metrics and the ongoing merger process suggest a period of uncertainty, warranting a 'hold' position until the merger's impact becomes clearer.

Keywords

Non-GAAP Financial Metrics, Adjusted EBITDA, Adjusted Gross Margin, Organon & Co., Financial Results, Merger, Supplemental Information, Quarterly Report